

## Subject Index to Volume 5 (1988)

- 3'-azidothymidine (AZT), 297  
 5-fluoro-2'-deoxyuridine, see FUdR  
 5-fluorouracil absorption, Ussing chamber analysis, 598  
 5-iodo-2'-deoxyuridine, see IDU  
 6-mercaptopurine, intraarterial infusion, 781  
 6-mercaptopurine, pharmacokinetics, 781  
 1,4-dihydropyridines, 655  
 absorption enhancers, colonic, 341  
 absorption rate constant, apparent first-order, 57  
 absorption rates, LOTUS 123 spreadsheet for, 247  
 absorption, food effects on theophylline, 48  
 absorption, nasal, 689  
 ACE inhibitor RS-10029, degradation kinetics, 765  
 ACE inhibitor RS-10029, degradation products, 765  
 acetaminophen metabolism, effects of tauroolithocholate, 61  
 acetaminophen, glucuronidation, 61  
 acetaminophen, sulfation, 61  
 acidosis, and gallapomil toxicity, 619  
 acrylate methacrylate copolymers, structure and permeability, 604  
 activated charcoal, adsorption of phenobarbital, 183  
 activation energy, epimerization in frozen solution, 266  
 adjuvant effects of bactivacin, 689  
 adjuvant effects of taurodihydrofusidate, 689  
 adjuvants, formulation, 523  
 adjuvants, reversible interaction with RBCs, 729  
 adjuvants, thermal interactions with RBCs, 729  
 adsorption, of phenobarbital by activated charcoal, 183  
 aerosol absorption from respiratory tract, 574  
 aerosol, inhalation and particle size, 36  
 aggregation mechanism, BCG vaccine, 607  
 aggregation number, BCG vaccine, 607  
 agonist-induced down-regulation, 795  
 albumin, cocaine binding, 440  
 aldose reductase inhibitor (AL-01576), protein binding, 319  
     AL01576, 261  
     pH-dependent binding, 319  
     serum binding in diabetes, 261  
 allometric equation, animal scale-up in pharmacokinetics, 668  
 alpha-1 glycoprotein, gallapomil binding, 619  
 alpha-1-acid glycoprotein (AAG), cocaine binding, 440  
 alpha-adrenergic receptors, spasmolytic binding studies, 430  
 alpha<sub>1</sub>-antitrypsin, recombinant, see rAAT  
 alveolar macrophage, quinidine accumulation in, 209  
 amino acid analysis in plasma, HPLC, 684  
 amino acid carrier, bovine brain endothelial cells, 369  
 amiodarone metabolism, 709  
 amiodarone, HPLC, 709  
 ampicillin, bioavailability, 634  
 ampicillin, prodrugs for improved shelflife, 288  
 anabolic steroids, separation and identification, 31  
 analysis, coupled steady state and nonsteady state, 92  
 angiotensin converting enzyme (ACE) inhibitor, RS-10029, 765  
 animal models, cat esophagus, 165  
     cat gastric mucosa, 165  
     gastrointestinal irritation, 165  
     rabbit colon, 165  
 animal scale-up in pharmacokinetics, 668  
 anthralin products (1%), oxygen diffusion studies, 92  
 antiarrhythmic agent ACC-9358, HPLC, 190  
 anticholinergic, oxyphencyclimine enantiomers, 236  
 antihypertensive activity, quinazolinone analogues, 242  
 antihypertensive drugs, whole blood analysis, 383  
 antimuscarinic activity of oxyphencyclimine, 236  
 antineoplastic agents, carmustine and lomustine, 220  
 antioxidants, cellular, 253  
 antipyrine clearance, dextromethorphan pretreatment, 437  
 antipyrine, pharmacokinetics, 437  
 antiretroviral drugs, AZT and DDT, 297  
 antiretroviral drugs, kinetics and biomedical impact, 297  
 antitussive agents, dextromethorphan pharmacokinetics, 437  
 ascorbate, effects on transdermal penetration, 738  
 asymmetric permeability, composite films, 604  
 AUC, i.v. plasma concentration, 57  
     oral plasma concentration, 57  
     tissue sampling compartments, 238  
 avidin, crosslinking with  $\kappa$ -receptor, 790  
 azathioprine, 6-mercaptopurine metabolite of, 781  
 azido drugs, biological reduction, 297  
 azone, percutaneous transport of isoproterenol, 116  
     effect on ocular levobunolol absorption, 238  
 AZT, biological reduction, 297  
  
 bacampicillin, bioavailability, 634  
 bacampicillin, prodrugs for improved shelflife, 288  
 Bacillus Calmette Guerin (BCG) vaccine, size characterization, 607  
 bacitracin, adjuvant effect on nasal absorption, 689  
     mucosal tolerance of, 689  
 baclofen, enantiospecific HPLC, 107  
     fluoro analogue, enantiospecific HPLC, 107  
     transport across brain endothelial cells, 369  
     urinary excretion, 107  
 bambuterol, biotransformation in lung, 151  
     uptake in lung, 151  
 basal metabolic rate, to correlate plasma clearance, 668  
 behavioral anomalies, and ethanol, 447  
 benzodiazepine receptor binding affinities, 408  
 benzodiazepines, pharmacokinetics, 201  
     QSAR for endogenous, 408  
 beta-adrenergic receptors, spasmolytic binding studies, 430  
 $\beta$ <sub>n</sub>-endorphin, biotin-avidin ELISA, 232  
 bile acid metabolism, effects of tauroolithocholate, 61  
 bioanalysis, dopamine receptors, 283  
 bioassay, intravenous for synthetic insulins, 245  
 bioavailability, beta estradiol, 44  
     cyclosporin A and erythrocyte binding, 80  
     intersubject variability, 322  
     naltrexone salicylate, 113  
     ocular levobunolol, 238  
     oral progabide, effect of gastric pH on, 226  
     theophylline, 48  
 biocytin-dynorphin,  $\kappa$ -opioid receptor probe, 790  
 bioequivalence, intersubject variability, 322  
     tissue sampling compartments, 238  
 biotin-avidin ELISA,  $\beta$ <sub>n</sub>-endorphin, 232  
 biotinylated receptor lipid, 790  
 bitterless prodrugs, buccal delivery of opioid analgesics, 615  
 bladder, spasmolytics, 430  
 blood plasma concentration, recombinant human interferon, 472  
 blood-brain barrier, carrier mediated transport, 369  
     estradiol delivery, 172  
 body surface area, to correlate plasma clearance, 668  
 boundary layer, mathematical model, 645  
 bovine brain, culture of endothelial cells, 369  
 brain DNA synthesis, and fetal alcohol syndrome, 447  
 brain-specific drug delivery, redox carriers, 172  
 bromodeoxyuridine (BUdR) incorporation *in vitro*, 518  
 bronchodilator, metered-dose powder inhaler, 506  
     bambuterol, 151  
     terbutaline, 151  
 buccal absorption, opioid analgesics, 615  
 buffer effect on dissolution, 272  
 bumetanide, acute tolerance of, 86  
     constant-rate infusion studies, 86  
     pharmacodynamics, 86  
     pharmacokinetics, 86  
 buserelin, nasal absorption with adjuvants, 689  
  
 calcium magnesium supplements, mineral metabolism, 501  
 calcium metabolism, calcium supplements and yogurt, 501

- cancer, diagnostics, 325
  - radiotherapy, 325
- capillary endothelial cells, drug targeting, 300
- caprate, sodium, colonic absorption promoter, 786
- carbadopa, duodenal administration, 587
  - pharmacokinetics, 578
  - rectal administration, 587
    - effect on systemic L-dopa levels, 587
- carmustine (BCNU), GC and thermionic N-P specific detection, 220
- carmustine, stability and pharmacokinetics, 220
- carrier systems, receptor-mediated magnetic chitosan, 300
- carrier-mediated absorption, fraction dose absorbed, 651
  - intestinal membrane, 651
- cat esophagus model, 165
- cat gastric mucosa model, 165
- catalase, oxygen radical scavenging, 253
- catalytic mechanism, bacterial cytochrome P450, 67
- cefazolin crystallinity, IR spectrometry, 426
  - X-ray diffractometry, 426
- cefazolin sodium pseudopolymorphs, 421
  - crystallinity of freeze dried, 421
  - hygroscopicity of, 421
- cefmetazole, colonic absorption enhancers, 341
- cefoxitin, rectal absorption enhancement, 453
- cephalosporins, intrinsic membrane absorption parameters, 645
- cephalosporins, oral absorption, 645
- cerebrospinal fluid, 401
- cerebrospinal fluid, cimetidine elimination from, 628
- chelated mineral supplements, retention and digestion, 501
- chemical delivery system, 172
- chemical kinetics, 288
- chemical structure/skin irritation, 660
- chemotherapeutic agents, antisense oligonucleotides, 539
- chiral drugs, enantiomeric inversion, 76
  - first-pass metabolism, 76
- chloride ion excretion, and furosemide, 694
- chlorthalozone, in CSF and serum, 401
  - pharmacodynamics, 401
  - skeletal muscle relaxant, 401
- cholestasis, tauroolithocholate induced, 61
- cholesterol, membrane permeability, 309
- choline uptake, inhibition by hemicholinium, 359
- choroid plexus, cimetidine transport, 628
- cimetidine, dissolution, 488
  - elimination from cerebrospinal fluid, 628
  - renal transport, 465
- clearance, cimetidine from cerebrospinal fluid, 628
- CNS, substance P down-regulation, 795
- cocaine, classes of binding sites, 440
- codeine, solubility parameters, 580
- colon permeability, passive absorption mechanism, 645
- colonic absorption promoters, sodium caprate and sodium caprylate, 786
- colonic absorption, cefmetazole, 341
  - inulin, 341
- colonic drug absorption, 341
- colonic drug absorption, transcellular permeation, 786
- colonic pore radius, drug absorption, 341
- colony forming units (CFU), BCG vaccine, 607
- compaction activity, effect on urease activity, 776
- compartmental model, nonlinear analysis, 156
- complexation, enhancement of nifedipine solubility, 655
- composite film pore structure, acrylate methacrylate copolymers, 604
- composite films, asymmetric permeability, 604
- composite films, pore structure, 604
- computer program, drug absorption rates, 247
- computer simulation, utilization time, 634
- controlled drug delivery, microspheres, 21
- controlled release dosage forms, effect of compaction, 776
- controlled release drug dosage forms, pHEMA hydrogels, 722
- controlled release, drug/polymer matrix, 488
  - microsphere release profiles, 178
  - theophylline, 48
- convection diffusion model, 495
- convolution integral, 57
- corticosteroids, topical, timobestone acetate, 704
- Coulter, size analysis comparison, 607
- creams, topical semisolid and oxygen diffusion studies, 92
- crystal structure, bacterial cytochrome P450, 67
- crystalline modification, vaccine adjuvants, 523
- crystalline transformation, cefazolin sodium, 421
- crystallinity, of freeze-dried cefazolin sodium, 421
- cumulative lymph recovery, recombinant human interferon, 472
- cutaneous blood, drug monitoring, 477
- cyanide antidote, methemoglobin, 749
- cyanide poisoning, pharmacokinetics, 749
- cyclic imides, hypolipidemic agents, 413
- cyclodextrin derivatives, water soluble, amorphous, 713
  - water soluble, and pharmaceutical usefulness, 713
- cyclosporin, *in vitro* model of intestinal absorption, 673
  - in vivo* model of intestinal absorption, 677
  - saturable binding to erythrocytes, 80
  - therapeutic drug monitoring, 80
- cytochrome P450, catalytic mechanism of bacterial, 67
  - crystal structure of bacterial, 67
  - dynamics of substrate binding, 67
  - inhibitor design of bacterial, 67
- cytokines, 129
- cytotoxicity, IDU prodrugs, 734
- decomposition products, stability indicating assay, 250
- deconvolution, model independent approach, 347
  - to quantify drug dissolution, 574
- degradation kinetics, parenteral prodrugs, 288
- derivative spectrophotometry, background absorption by excipients, 709
- derivative spectrophotometry, first and second order, 709
- desethylamiodarone, HPLC, 709
- detirelix pharmacokinetics, 335
- dextromethorphan, antipyrine clearance, 437
  - pharmacokinetics, 437
- di(2-ethylhexyl)phthalate, HPLC, 10
  - pharmacokinetics, 10
- diabetes, glucosylated albumin, 261
  - serum protein binding of drugs, 261
- diagnostic localization, radiolabeled antibodies, 325
- diastereoisomer separation, HPLC for fenoprofen enantiomers, 53
- diazepam, serum binding in diabetes, 261
- diclofenac sodium, dissolution, 488
- diclofenac transdermal penetration, effect of ascorbate on, 738
  - effects of dithiothreitol on, 738
- differential scanning calorimetry, RBCs, 729
- diffusion cell, gastrointestinal tissue, 372
  - iontophoretic for *in vitro* studies, 443
- diffusion characteristics of hydrogels, 592
- diffusion transport mechanisms, oxygen in creams, 92
- diffusion, from 2-phase emulsion type ointment, 16
  - topical thin applications, 377
- difluoromethylornithine (DFMO), HPLC, 684
- dihydropyridines, 172
- diisopropylfluorophosphate, esterase inhibition, 623
- diprophylline, dissolution, 488
- disintegration time, enteric coating, 550
- disopyramide, stereoselective binding, 316
- dissolution, drug/polymer matrix, 488
- dithiothreitol (DTT), 297
  - effects on transdermal penetration, 738
- diuretic response, quantitative measure of, 694
- DNA binding, nitrenium ion to nitrofurazone, 434
- dopamine agonist N-0437, radioreceptor assay, 283
- dopamine receptors, radioreceptor assay, 283
- dopaminergic bioactivity assay, 283
- dosage form design, gastric retention times, 533
- dosage form design, physical parameters, 533
- dose accountability, percutaneous absorption, 313
- down-regulation, agonist-induced for substance P, 795
- drug delivery system, porous biodegradable microspheres, 21
  - implantable pump for intrarenal infusion, 781
  - liposomes as, 759

- drug delivery, iontophoresis, 251  
 drug design, 397  
     P450 as model system for, 67  
 drug dissolution, buffer effects, 272  
     film model for, 272  
     ionization effects in buffered, 272  
     ionization effects in unbuffered, 272  
 drug metabolism, enzyme induced dextromethorphan, 437  
 drug monitoring, cutaneous blood, 477  
 drug screening, systematic, 397  
 drug solubilization, liposome system for, 759  
 drug stability testing, interpretation, 249  
 drug stability, initial rate method, 249, 250  
 drug transport, topical thin applications, 377  
 drug/polymer matrix swelling and dissolution, 488  
 drugs, sparingly soluble, ionization constants, 772  
     sparingly soluble, limiting solubilities, 772  
 DTT, biological reduction, 297
- effects of gender, posture, and age, 639  
 electrode material for iontophoresis, 251  
 elimination of hydrocarbons, P450, 67  
 ELISA,  $\beta_h$ -endorphin, 232  
 elixirs, phenobarbital, 803  
 emulsion-type ointment, two-phase, 16  
 enantiomeric inversion, chiral NSAIDs, 76  
     ibuprofen, 40  
 enantioselective HPLC for warfarin, 680  
 endothelial cells, blood-brain barrier transport, 369  
 enhancement, skin absorption, 753  
 enzymatic hydrolysis of FUDR esters, 741  
 enzyme induction, dextromethorphan, 437  
 ephedrine diastereoisomers, thermodynamics, 391  
 ephedrine enantiomers, thermodynamics, 391  
 ephedrine, solubility, 391  
 epimerization in frozen solution, activation energy, 266  
 epimerization, moxaolactam in frozen solution, 266  
 equilibrium distribution model for micellar solubilization, 704  
 erythrocytes, saturable binding of cyclosporin to, 80  
 esmolol, secondary buffer system from degradation, 514  
 ester prodrugs, enzyme specificity, 741  
     hydrolysis of, 741  
 esterase inhibition, diisopropylfluorophosphate, 623  
 estradiol, CNS-directed, 172  
     first pass metabolism, 44  
     oral bioavailability, 44  
     prodrugs, 44  
 ethanol-water mixtures, solubility equation, 193
- fatty acids, rectal absorption enhancement of medium chain, 453  
 fenoprofen enantiomers, pharmacokinetics, 53  
 fenoprofen, HPLC for diastereomeric separation, 53  
 fentanyl, solubility parameters, 580  
 fetal alcohol syndrome, brain DNA synthesis, 447  
 film model for dissolution, 272  
     absorption, 651  
     release kinetics, 550  
 first-pass metabolism, beta estradiol, 44  
     chiral NSAIDs, 76  
 fluid mechanics and dissolution rate, 495  
 fluorescein, dissolution in isolated lung, 574  
 fluorescence polarization, for membrane perturbation studies, 786  
 flurbiprofen enantiomers, HPLC, 123  
 food effects, theophylline controlled release, 48  
 formulation design, enteric coating, 550  
 formulation, effect on particle size distribution, 36  
     oxygen sensitive drugs, 92  
     particulate rAAT, 800  
 fraction dose absorbed, carrier-mediated compounds, 651  
     passive absorption, 651  
 free volume, hydrogels, 592  
 freeze drying, cefazolin sodium, 421, 426  
 Freundlich model, 183  
 frozen solution, epimerization in, 266  
 FUDR ester prodrugs, nonenzymatic and enzymatic hydrolysis of, 741
- functional group contributions in transport through SC, 566  
 furosemide, effect on urinary electrolyte excretion, 694  
 increased response during acute renal failure, 699  
 urinary excretion of, with dopamine coadministration, 699
- gallapomil protein binding, effect of pH, 619  
 gas chromatography, see GC  
 gas chromatography, stereospecific assay for ibuprofen, 40  
 gastric emptying, nondisintegrating geometric shapes, 533  
     pharmacokinetics, 533  
 gastric residence time, effects of gender, posture, and age on, 639  
 gastric transit time, Heidelberg capsule, 639  
     radiotelemetry, 639  
 gastrointestinal irritation, 165  
     doxycycline, 165  
     potassium chloride, 165  
     propranolol, 165  
 gastrointestinal permeability, *in vitro* measurement, 372  
 gastrointestinal therapeutics system, 165  
 gastrointestinal tissue, diffusion cell, 372  
 GC, capillary with electron capture for GTN metabolites, 99  
     of BCNU and CCNU, 220  
 genetic diseases, 199  
 glucocorticoid receptors, in human synovial tissue, 623  
 glucocorticoid-21-esters, relative receptor affinity, 623  
 glucocorticoids, comparative pharmacokinetics at high doses, 509  
 glucose monitor in dog, intravenous, 245  
 glucosylated albumin, in diabetes, 261  
 glucuronidation, acetaminophen, 61  
 glycerides, medium chain and membrane permeability, 309  
 gonadorelin, nasal absorption with adjuvants, 689  
 graph theoretical approach, endogenous benzodiazepines, 408  
 guanidino moiety, antihypertensive activity, 242  
 gut metabolism ibuprofen enantiomers, 40
- Heidelberg capsule, gastric transit time, 639  
 helix-coil equilibrium in gelatin microcapsules, 726  
 hemicholinium congeners, structure-activity relationship, 359  
 heparin complex with chitosan microspheres, 300  
 hepatic conjugation, and tauroolithochlate, 61  
 hereditary diseases, 199  
 hexamethylene lauramide, disposition, 477  
 hexamethylene lauramide, skin penetration enhancer, 477  
 HIAC/Royco, size analysis comparison, 607  
 high density lipoprotein (HDL) receptor activity, 413  
 high pressure liquid chromatography, see HPLC  
 HPLC, with electrochemical detection, spectinomycin, 664  
     with electrochemical detection, trobicin, 664  
     achiral/chiral warfarin enantiomers, 680  
     amino acid analysis in plasma, 684  
     amiodarone, 709  
     antiarrhythmic agent ACC-9358, 190  
     chiral stationary phase, 187  
     CNS-directed estradiol, 172  
     desethylamiodarone, 709  
     di(2-ethylhexyl)phthalate, 10  
     difluoromethylornithine (DFMO), 684  
     enantiospecific for baclofen, 107  
     fenoprofen diastereomeric separation, 53  
     flurbiprofen enantiomers, 123  
     hydralazine, 383  
     muramyl dipeptide, 528  
     phenobarbital, 803  
     precolumn derivatization with o-phthalaldehyde, 684  
     precolumn enrichment, 172  
     propranolol enantiomers, 187  
     quazepam metabolites, 365  
     whole blood analysis, 383  
     human plasma, HPLC for antiarrhythmics in, 190  
     human serum albumin, gallapomil binding, 619  
     Humulin R, biological activity compared to Novolin R, 245  
     Humulin R, intravenous bioassay for, 245  
     hydralazine, HPLC, 383  
     p-nitrobenzaldehyde derivatization, 383  
     hydrocortisone alcohol, dissolution rate studies, 495  
     hydrocortisone esters, partition coefficients in stratum corneum, 566

- uptake by stratum corneum, 140
- hydrocortisone, saliva analysis for endogenous, 509
- skin penetration enhancement, 477
- hydrogels, diffusion characteristics, 592
  - free volume, 592
  - pH-dependent swelling, 592
  - poly(hydroxyethyl methacrylate-CO-methacrylic acid), 592
- hydrolysis kinetics, bacampicillin, 288
  - talampicillin, 288
- hydromorphone, bioavailability, 718
  - intravenous administration, 718
  - nasal administration, 718
  - oral administration, 718
  - pharmacokinetics, 718
  - solubility parameters, 580
  - transdermal administration, 718
- hygroscopicity, cefazolin sodium, 421
- hypolipidemic agents, cyclic imides, 413
  - lipoprotein degradation, 413
  - receptor activity, 413
- i.v. coadministration of carbadopa and L-dopa, 587
- ibuprofen enantiomers, pharmacokinetics, 40
- ibuprofen, enantiomeric inversion, 40, 76
  - gut metabolism, 40
  - pharmacokinetics, 76
  - presystemic inversion, 40
  - stereospecific gas chromatographic technique, 40
- IDU prodrugs, cytotoxicity, 734
  - physicochemical properties, 734
  - synthesis, 734
- immunoinflammatory response, 129
- immunosuppressive drug administration, intraarterial, 781
- immunotherapy, and monoclonal antibodies for, 1
- in vitro* apparatus, gastrointestinal tissue permeability, 372
- in vitro* model, cyclosporin intestinal absorption, 673
- in vivo* model, cyclosporin intestinal absorption, 677
- indigestible solid, Heidelberg capsule, 639
- indomethacin microspheres, 178
- indomethacin, transdermal administration, 103
- inflammation, interleukin 1, 129
  - tumor necrosis factor, 129
- infrared (IR), cefazolin sodium, 426
- inhalation aerosol, output particle size distribution, 36
- inhaler, metered-dose powder, 506
- inhibitor design, bacterial cytochrome P450, 67
- initial rate method, drug stability, 249, 250
- inspiratory flow rate, and metered-dose powder inhaler, 506
- insulin, synthetic human, 245
- interleukin 1 and inflammation, 129
- intersubject variability, bioavailability/bioequivalence, 322
- intestinal absorption, 5-fluorouracil, 598
  - in vitro* model for cyclosporin, 673
  - in vivo* model for cyclosporin, 677
- intestinal membrane permeability, 651
- intestinal metabolism, Ussing chamber analysis, 598
- intestinal transport, Ussing chamber analysis, 598
- intraarterial infusion of immunosuppressive drugs, 781
- intra gastric pH measurement via radiotelemetry, 639
- intravenous administration of hydromorphone, pharmacokinetics, 718
- intrinsic membrane absorption parameters, mathematical model, 645
- inulin, colonic absorption enhancers, 341
- ionization constants, using potentiometric titration, 772
- iontophoresis, diffusion cell for, 443
  - electrode material, 251
- isoproterenol, partition coefficient, 116
  - percutaneous transport, 116
  - solubility, 116
  - stability, 116
- $\kappa$ -opioid receptor probe, biocytin-dynorphin, 790
- ketorolac, percutaneous absorption, 457
- kidney, membrane transport, 465
- kinetics of release, film model, 550
  - kinetics of replacement, thymidine by BUdR, 518
- L-dopa, effect of carbadopa on systemic levels, 587
- Langmuir equation, 183
- levobunolol, effect of azone on ocular absorption, 238
- linear free-energy relationships, nifedipine solubility, 655
- lipid digestion, cyclosporin lipid vehicle, 673, 677
- lipid domains, in stratum corneum, 140
- lipid emulsion, prostaglandin E<sub>1</sub>, 482
- lipid peroxidation, enzyme mediated repair, 253
  - oxygen free radicals, 253
- lipid regulatory enzymes, 413
- lipid uptake, stratum corneum, 566
- lipid vehicle, cyclosporin intestinal absorption, 673, 677
- lipophilic drug delivery systems, 759
- liposomal uptake, membrane permeability studies, 309
- liposomes as particulate drug carriers, 352
- liposomes, drug delivery systems, 759
- lomustine (CCNU), GC and thermionic N-F specific detection, 220
  - stability and pharmacokinetics, 220
- lonapalene, antipsoriatic application, 16
  - in two phase emulsion-type ointment, 16
- loop diuretics, quantitative measure of diuretic response, 694
- LOTUS 123, spreadsheet for absorption rates, 247
- low density lipoprotein (LDL) receptor activity, 413
- lucifer yellow CH, human neutrophilic uptake, 352
- lung biotransformation of bambuterol, 151
- lung, cellular and subcellular distribution of quinidine in, 209
  - drug dissolution or release, 574
- luteinizing hormone-releasing hormone (LHRH), 689
  - agonist, 689
  - antagonist, 335
- lymph concentration, recombinant human interferon, 472
- magnesium calcium supplements, mineral metabolism, 501
- mass balance, percutaneous absorption, 313
- mass spectrometry, collision-activated dissociation, 31
- mathematical model, drug/polymer matrix analysis, 488
  - intrinsic membrane absorption parameters, 645
- mean residence time, Michaelis-Menten elimination, 156
  - Michaelis-Menten kinetics, 196
- medicinal chemistry, drug design, 397
- membrane permeability, medium chain glycerides, 309
- membrane perturbation, by sodium caprate, 786
  - fluorescence polarization, 786
- membranes, adjuvant effects on RBC, 729
- membranous microviscosity, medium chain glycerides, 309
- meperidine, solubility parameters, 580
- metabolic derivatives of progabide, 226
- metabolism, bambuterol in lung, 151
- metabolite formation, pharmacokinetics, 347
- metal ions and iontophoresis, 251
- methemoglobin, cyanide antidote, 749
- methylprednisolone hemisuccinate, pharmacokinetics, 509
- methylprednisolone phosphate, pharmacokinetics, 509
- micellar solubilization, equilibrium distribution model, 704
- micelle formation, change of water structure and, 726
- micelles, critical micelle concentration determination, 726
- Michaelis-Menten elimination, mean residence time, 156
  - one compartment, 196
- microcapsule disintegration, and helix-coil equilibrium, 726
- microspheres, controlled release, 21
  - heparin complexing with chitosan, 300
- indomethacin, 178
  - magnetic chitosan and receptor targeting, 300
  - poly(glycolic) acid, 21
  - porous as drug delivery system, 21
  - processing conditions, 21
  - release profiles, 178
  - solvent removal techniques, 21
- microviscosity, medium chain glycerides, 309
- micturitional disorders, spasmolytics, 430
- mini-swine, model for food effects on theophylline absorption, 48
- mixed solvents, solubility equation, 193
- model independent approach to deconvolution, 347

- moment analysis, 57  
 compared to nonlinear analysis, 156  
 monoclonal antibodies, radionuclide selection for, 325  
 therapeutic applications, 1  
 morphine, solubility parameters, 580  
 moxalactam, epimerization in frozen solution, 266  
 muramyl dipeptide, amorphous and crystalline characterization, 523  
 HPLC, 528  
 hydrolysis kinetics, 528  
 mutarotation, 523  
 parenteral formulation, 528  
 pH of maximum stability, 528  
 thermal reactivity, 528  
 muscarinic receptors, spasmodic binding studies, 430  
 mutarotation, muramyl dipeptide, 523  
*Mycobacterium bovis* BCG (*Bacillus Calmette Guérin*), 607
- nalbuphine, bitterless prodrugs of, 615  
 naltrexone salicylate, bioavailability, 113  
 naltrexone, prodrug bioavailability, 113  
 prodrug pharmacokinetics, 113  
 prodrug synthesis, 113  
 narcotic analgesics, transdermal delivery, 580  
 solubility parameters, 580  
 narcotic antagonist, buccal absorption, 615  
 nasal absorption, bacitracin as adjuvant for, 689  
 buserelin, 689  
 gonadorelin, 689  
 taurodihydrofusidate as adjuvant for, 689  
 nasal administration of hydromorphone, pharmacokinetics, 718  
 of peptide drugs, 689  
 nephrocalcinosis, calcium phosphate dibasic, 501  
 neuromuscular inhibition, hemicholinium, 359  
 neutrophils, phagocytosis, 352  
 pinocytosis, 352  
 targets for drug delivery, 352  
 nifedipine, percutaneous absorption, 457  
 nifedipine solubility, enhancement via complexation, 655  
 complexation with substituted phenolic ligands, 655  
 nitrenium ion, DNA binding to nitrofurazone, 434  
 nitrofurazone, DNA binding of nitrenium ion, 434  
 nitroglycerin denitration products, capillary GC analysis, 99  
 NMR, <sup>13</sup>C cross-polarization/magic angle spinning, 611  
 NMR, solid state for skin hydration, 611  
 noncompartmental analysis without theoretical approximation, 57  
 nonlinear regression analysis, 57  
 nonsteroidal antiinflammatory drugs, chiral, 76  
 see NSAIDs  
 nonsteroidal antipsoriatic agent, lonapalene, 16  
 Novolin R, biological activity compared to Humulin R, 245  
 Novolin R, intravenous bioassay for, 245  
 NSAIDs, antipsoriatic application, 16  
 enantiomeric inversion, 76  
 fenoprofen, 53  
 first-pass metabolism of chiral, 76  
 pharmacokinetics of chiral, 76  
 nuclear magnetic resonance, see NMR
- occlusion, percutaneous absorption, 313  
 ointment, 2-phase emulsion type, 16  
 USP XXI hydrophilic, oxygen diffusion study, 92  
 oligonucleotide analogues, translation arrest, 539  
 one-compartment model, Michaelis-Menten kinetics, 196  
 opiate receptors, spasmodic binding studies, 430  
 opioid analgesics, buccal absorption, 615  
 opioids, solubility parameters, 580  
 oral absorption,  $\beta$ -lactam antibiotics, 645  
 cephalosporins, 645  
 oral administration of hydromorphone, pharmacokinetics, 718  
 oral administration, utilization time, 634  
 organic cation transport, 465  
 oxidative enzyme activity, paralysis time, 401  
 oxygen diffusion studies, anthralin products (1%), 92  
 oxygen diffusion transport mechanism, creams, 92  
 oxygen diffusion, coupled steady state and nonsteady state, 92  
 oxygen free radical scavenging enzymes, 253  
 oxygen free radicals, paraquat toxicity, 253  
 toxic effects, 253  
 oxygen sensitive drugs, formulation design, 92  
 oxyphencyclimine enantiomers, antimuscarinic activity, 236  
 oxyphencyclimine enantiomers, relative potency, 236
- PAH, renal metabolism, 745  
 PAH, renal transport, 745  
 para-aminohippurate, see PAH  
 paracellular permeation, colonic drug absorption, 341  
 pore radius, 341  
 paralysis time, oxidative enzyme activity, 401  
 paraquat toxicity, oxygen free radicals, 253  
 parenteral administration, recombinant human interferon, 472  
 utilization time, 634  
 parenteral prodrugs, hydrolysis of, 288  
 particulate drug carriers, liposomes as, 352  
 isoproterenol, 116  
 in stratum corneum, 566  
 prostaglandin E<sub>1</sub>, 482  
 solutes into stratum corneum, 140  
 passive absorption mechanism, colon, 645  
 fraction dose absorbed, 651  
 intestinal membrane, 651  
 penetrant physical chemistry, 753  
 penetration enhancer, hexamethylene lauramide, 477  
 azone, 238  
 simultaneous application, 457  
 peptide drugs, ACE inhibitor, 765  
 nasal administration, 689  
 percutaneous absorption, classical diffusion model, 753  
 dose accountability, 313  
 ketorolac, 457  
 mass balance, 313  
 nifedipine, 457  
 nonocclusive, 313  
 simple kinetic analysis, 753  
 percutaneous penetration, physicochemical aspects, 753  
 percutaneous transport, isoproterenol, 116  
 permeation routes, transcellular, 786  
 pH change, controlled by secondary buffer system, 514  
 pH profiles, 288  
 pH, skin permeation, 660  
 pH-dependent binding, aldose reductase inhibitor, 319  
 pH-dependent swelling of hydrogels, 592  
 phagocytosis, human neutrophils, 352  
 pharmacodynamics, bumetanide, 86  
 chorzoxazone, 401  
 phenylpropanolamine, 120  
 zoxazolamine, 401  
 pharmacokinetics, 6-mercaptopurine (6-MP), 781  
 animal scale-up in, 668  
 benzodiazepines, 201  
 bumetanide, 86  
 carmustine and lomustine, 220  
 chiral NSAIDs, 76  
 cimetidine, 628  
 cyanide poisoning, 749  
 deconvolution for metabolite formation, 347  
 detirelix (LHRL antagonist), 335  
 dextromethorphan, 437  
 di(2-ethylhexyl)phthalate, 10  
 disopyramide stereoisomers, 316  
 fenoprofen enantiomers, 53  
 gastric emptying, 533  
 glucocorticoids at high doses, 509  
 ibuprofen enantiomers, 40  
 LOTUS 123 spreadsheet for absorption rates, 247  
 mean residence time, 156, 196  
 methylprednisolone hemisuccinate, 509  
 methylprednisolone phosphate, 509  
 Michaelis-Menten elimination, 156  
 naltrexone salicylate, 113  
 phenprobamate, 387

- phenylpropanolamine, 120
- quazepam metabolites, 365
- renally transported drugs, 465
- topological approach, 201
- phase distribution pH dependent of prostaglandin E<sub>1</sub>, 482
- phase-volume ratio, 92
- pHEMA (polyhydroxy ethyl methacrylate), 722
- pHEMA hydrogels, elastic solution, 722
  - glass transition, 722
  - melting enthalpy, 722
  - thermal analysis of, 722
- phenobarbital, adsorption, 183
  - alternatives for elixirs, 803
  - dosage form stabilities, 803
  - HPLC, 803
  - solubility, 803
- phenol red, membrane permeability studies, 309
- phenprobamate, time-dependent kinetics, 387
- phenylpropanolamine disposition, urinary pH modification, 120
- phenylpropanolamine, drug interactions, 120
  - pharmacodynamics, 120
  - pharmacokinetics, 120
  - renal tubular secretion, 120
- phenytoin, serum binding in diabetes, 261
- phosphatidylserine, effect on quinidine distribution in lung, 209
- pinocytosis, fluid-phase of human neutrophils, 352
- piretanide, effect on urinary electrolyte excretion, 694
- pKa, relation to skin irritation, 660
- plasma clearance, correlation between humans and rats, 668
- plasma membrane, quinidine accumulation in, 209
- plasma proteins, binding of disopyramide, 316
- poly hydroxy ethyl methacrylate, see pHEMA
- poly(glycolic) acid microspheres, 21
- polymer matrix swelling, 488
- potassium ion excretion, and furosemide, 694
- potentiometric titration, antidepressants, 772
  - nucleoside transport inhibitors, 772
  - sparingly soluble drugs, 772
- presystemic inversion, ibuprofen enantiomers, 40
- procainamide metabolites, pharmacokinetics, 347
- prodrug design, 634
- prodrug synthesis, naltrexone salicylate, 113
- prodrugs for buccal delivery of opioid analgesics, 615
- prodrugs, beta estradiol, 44
  - improved shelflife for parenterals, 288
  - improvement in shelf life, 634
- progabide, oral bioavailability and gastric pH, 226
  - stability and solubility, 226
- propranolol, enantioselective HPLC, 187
  - detection of serum levels, 187
  - serum binding in diabetes, 261
- prostacyclin analogue degradation, alkene hydration, 214
  - pH effect, 214
  - proton transfer, 214
- prostacyclin analogue lactonization, 214
- prostacyclin analogues, stability, 214
- prostaglandin E<sub>1</sub>, lipid emulsion, 482
  - partition coefficients, 482
  - pH dependent phase distribution, 482
- protein aggregation, rAAT, 800
- protein binding, cocaine, 440
  - pH dependence, 319
- protein domains, in stratum corneum, 140
- protein drugs, controlled release forms, 776
  - monoclonal antibodies as, 1
- protein thiol, effects on transdermal penetration, 738
- protein uptake, stratum corneum, 566
- proximal tubule transport, 465
- pseudopolymorphs, hygroscopicity of cefazolin sodium, 421
- psoriasis, NSAIDs for, 16
- pump, intrarenal infusion, 781
- pyridinium salts, quaternary, 172
- QSAR, benzodiazepines, 201
- QSAR, structural similarity of 1,4-benzodiazepines, 408
- quantitative structure-activity analysis, see QSAR
- quazepam metabolites, pharmacokinetics, 365
- quazepam, sublingual administration, 365
- quinazolinone analogues, antihypertensive activity of, 242
- quinazolinones, synthesis of 2-substituted 4(3H)-, 242
- quinidine distribution, role of phosphatidylserine, 209
- quinidine, distribution in lung, 209
  - in alveolar macrophages, 209
  - in plasma membrane of lung, 209
- rAAT, particulate formation, 800
  - physical stability of, 800
  - protein aggregation, 800
  - shelf life prediction of injectable, 800
- rabbit colon model, 165
- radionuclides, tumor-targeted delivery, 325
- radioreceptor assay, dopamine receptors, 283
- radiotelemetry, intragastric pH measurement, 639
- rat brain slices, incubation with substance P, 795
- rat sandwich skin-flap model, 477
- REC 15/2053 (flavone derivative), receptor binding studies, 430
- receptor affinity for glucocorticoid-21 esters, 623
- receptor binding studies, flavone and derivatives, 430
- receptor targeting, magnetic chitosan microspheres, 300
- receptor-avidin crosslinking, 790
- receptor-mediated magnetic carriers, 300
- recombinant DNA technology, 199
- recombinant DNA, synthetic human insulin, 245
- recombinant human interferon  $\alpha$ -2a (rIFN  $\alpha$ -2a), delivery to lymph, 472
- rectal absorption enhancement, medium chain fatty acids, 453
- red blood cells, adjuvant-membrane interaction model, 729
- red blood cells, induced transition temperature and adjuvant effects, 729
- reduced 3-suffix solubility equation, 193
- reductive metabolism, xanthine oxidase-catalyzed anaerobic, 434
- relaxants, skeletal muscle, 401
- release profile, cumulative for microspheres, 178
- release, from 2-phase emulsion type ointment, 16
- renal drug transport, cimetidine, 465
  - methodology, 465
- renal epithelia, transport processes, 465
- renal failure, acute and furosemide response, 699
  - and di(2-ethylhexyl)phthalate, 10
- renal metabolism of PAH, 745
- renal transplantation in dogs, 781
- renal transport of PAH, 745
- renal transport, site identification techniques, 465
- renal tubular secretion, phenylpropanolamine, 120
- respiratory tract, drug dissolution or release, 574
- righting reflex, loss of and skeletal muscle relaxants, 401
- saliva analysis, endogenous hydrocortisone, 509
- saturation level, of 2-phase emulsion type ointment, 16
- secondary buffer, aliphatic carboxy ester of esmolol, 514
- serotonergic receptors, spasmolytic binding studies, 430
- serum protein binding, aldose, reductase inhibitor, 261
  - diazepam, 261
  - in diabetes, 261
  - phenytoin, 261
  - propranolol, 261
- shelf life prediction, injectable rAAT, 800
- shelf life, prodrug approach, 288
  - prodrugs to improve, 634
- size analysis, BCG vaccine, 607
  - Coulter and HIAC/Royco comparison, 607
- skeletal muscle relaxants, loss of righting reflex, 401
- skin flap, skin penetration of hydrocortisone, 477
- skin hydration, NMR analysis, 611
- skin irritation, relationship to pK<sub>a</sub>, 660
- skin penetration, hexamethylene lauramide, 477
  - transport kinetics, 753
- skin permeation enhancers, indomethacin, 103
- sodium ion excretion, and furosemide, 694
- solid phase extraction from plasma, 365

- solubility of nifedipine, enhancement via complexation, 655  
 solubility parameters, narcotic analgesics, 580  
 solubility, IDU prodrugs, 734  
 solubility, isoproterenol, 116  
 solubility, limit using potentiometric titration, 772  
 solubility, progabide, 226  
 solubilizing capacity of nonionic surfactants, 704  
 solute absorption from respiratory tract, 574  
 sparingly soluble drugs, ionization constants, 772  
   limiting solubilities, 772  
   potentiometric titration data, 772  
 spasmolytics, flavone and derivatives, 430  
 spasmolytics, receptor binding affinities, 430  
 spectinomycin, HPLC with electrochemical detection, 664  
 spectrophotometry, first and second order derivative, 709  
 squamous carcinoma cells, BUdR incorporation, 518  
 stability indicating assay, carmustine and lomustine, 220  
   initial rate method, 249  
 stability, ampicillin, 288, 634  
   bacampicillin, 288, 634  
   isoproterenol, 116  
   progabide, 226  
   rAAT, 800  
   secondary buffer system for degradation, 514  
   talampicillin, 288, 634  
 stability-indicating assay, initial rate method, 250  
   interpretation, 249  
 stationary disk/rotating fluid system, dissolution rate, 495  
 steady-state analysis, topical semisolid creams, 92  
 stereoisomers, binding to plasma proteins, 316  
 stereoselective binding, disopyramide, 316  
 stereospecific analysis, fenoprofen, 53  
 stratum corneum uptake mechanisms, 140  
 stratum corneum, lipid domains and solute uptake, 140  
   permeability-partition coefficients, 566  
   protein and lipid uptake, 566  
   protein domains and solute uptake, 140  
   uptake of hydrocortisone esters, 140  
   water of hydration, 140  
 streptozotocin, effect on serum protein binding of drugs, 261  
 structural similarity and binding affinity, 408  
 sublingual administration, quazepam, 365  
 substance P binding technique, tritiated, 795  
 substance P receptor down-regulation, 795  
 sufentanil, solubility parameters, 580  
 sulfation, of acetaminophen, 61  
 superoxide dismutase, oxygen radical scavenging, 253  
 surfactant, effect on particle size distribution, 36  
 surfactants, fatty acid esters (Myrj), 704  
   fatty alcohol ethers (Brij), 704  
   nonionic, solubilizing capacity of, 704  
   polyoxyethylen sorbitan monofatty acid esters, 704  
 synovial tissue, glucocorticoid receptors, 623  
   receptor affinities, 623  
 systemic disposition, hexamethylene lauramide, 477  
  
 tablets, enteric coated, 550  
 talampicillin, bioavailability, 634  
   prodrugs for improved shelflife, 288  
 targeted drug delivery, intrarenal infusion pump, 781  
   lymphoid cells, 472  
   recombinant human interferon, 472  
   therapeutic radionuclides, 325  
   to human neutrophils, 352  
 targeted drugs, chemotherapeutic agents, 539  
 targeting, biochemical and physical means, 300  
   capillary endothelial cells, 300  
   receptor-mediated magnetic carriers, 300  
 taste receptors and prodrugs, 615  
 taurodihydrofusidate, adjuvant effect on nasal absorption, 689  
 tauroolithocholate, effect on metabolism of acetaminophen, 61  
 teratogenic anomalies, and ethanol, 447  
 terbutaline sulfate, metered dose powder inhaler, 506  
  
 terbutaline, as prodrug bambuterol, 151  
 testosterone esters, collision-activated dissociation mass spect., 31  
   in imported oil injectables, 31  
   structural determination in oil, 31  
   thermospray, 31  
 theophylline, controlled release, 48  
 therapeutic drug monitoring, cyclosporin A, 80  
 thermal interactions of adjuvants on RBC membranes, 729  
 thermionic N-P specific detection with CG analysis, 220  
 thermodynamics, ephedrine diastereoisomers, 391  
   solubility predictions of binary mixtures, 391  
 thermospray, 31  
 thymidine replacement kinetics in squamous carcinoma cells, 518  
 time-dependent kinetics, multiple dosing, 387  
   phenprobamate, 387  
 timobesone acetate, micellar solubilization of, 704  
   solubility, 704  
 tissue concentrations, 238  
 tolerance, acute of bumetanide, 86  
 topical dosage forms, transport, 377  
 topological approach, endogenous benzodiazepines, 408  
   pharmacokinetics, 201  
 transdermal administration, indomethacin, 103  
   of hydromorphone, pharmacokinetics, 718  
 transdermal delivery, isoproterenol, 116  
   narcotic analgesics, 580  
 transdermal drug delivery, enhancement, 103  
   indomethacin, 103  
   iontophoretic diffusion cell, 443  
 transdermal penetration of diclofenac, 738  
 transdermal penetration, excised rat dorsal skin, 738  
 transepidermal water loss, 313  
 translation arrest, oligonucleotide analogues, 539  
 transport kinetics, skin penetration, 753  
 transport, cimetidine through choroid plexus, 628  
 transport, functional group contributions, 566  
 trobicin, degradation product of spectinomycin, 664  
   HPLC with electrochemical detection, 664  
 tumor antigens, radiolabeled antibodies to, 325  
 tumor necrosis factor and inflammation, 129  
 Turbuhaler, low inspiratory flow rates, 506  
   metered-dose powder inhaler, 506  
  
 ultrafiltration, phase distribution of prostaglandin E<sub>1</sub>, 482  
 unbound plasma clearance, correlation between humans and rats, 668  
 unsteady-state analysis, topical semisolid creams, 92  
 uptake mechanisms, stratum corneum, 140  
 urease activity, effect of dry-state compactional pressure, 776  
 urinary electrolytes in rats, 694  
 urinary excretion of furosemide, 699  
 urinary excretion, baclofen, 107  
 urinary pH modification, phenylpropranolamine disposition, 120  
 Ussing chamber, intestinal transport and metabolism, 598  
 utilization time, bacampicillin, 288  
   computer simulation, 634  
   talampicillin, 288  
  
 vaccine adjuvants, formulation, 523  
 ventriculocisternal perfusion, 628  
 volume fraction, internal phase of 2-phase emulsion ointment, 16  
  
 warfarin enantiomers, HPLC, 680  
   serum levels, 680  
 water of hydration, stratum corneum, 140  
  
 X-ray diffractometry, cefazolin sodium, 426  
 xanthine oxidase-catalyzed anaerobic reduction, 434  
 xenobiotic molecules, metabolism and P450, 67  
  
 zoxazolamine, in CSF and serum, 401  
   oxidative enzyme activity, 401  
   pharmacodynamics, 401